Regulation of ligands for the activating receptor NKG2D

被引:118
作者
Mistry, Anita R. [1 ]
O'Callaghan, Chris A. [1 ]
机构
[1] Univ Oxford, Henry Wellcome Bldg Mol Physiol, Oxford OX3 7BN, England
基金
英国医学研究理事会;
关键词
NKG2D; activating receptor; MICA; RAET1; UL16;
D O I
10.1111/j.1365-2567.2007.02652.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The outcome of an encounter between a cytotoxic cell and a potential target cell depends on the balance of signals from inhibitory and activating receptors. Natural Killer group 2D (NKG2D) has recently emerged as a major activating receptor on T lymphocytes and natural killer cells. In both humans and mice, multiple different genes encode ligands for NKG2D, and these ligands are non-classical major histocompatibility complex class I molecules. The NKG2D-ligand interaction triggers an activating signal in the cell expressing NKG2D and this promotes cytotoxic lysis of the cell expressing the ligand. Most normal tissues do not express ligands for NKG2D, but ligand expression has been documented in tumour and virus-infected cells, leading to lysis of these cells. Tight regulation of ligand expression is important. If there is inappropriate expression in normal tissues, this will favour autoimmune processes, whilst failure to up-regulate the ligands in pathological conditions would favour cancer development or dissemination of intracellular infection.
引用
收藏
页码:439 / 447
页数:9
相关论文
共 93 条
  • [1] Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D Ligands by the histone deacetylase inhibitor sodium valproate
    Armeanu, S
    Bitzer, M
    Lauer, UM
    Venturelli, S
    Pathil, A
    Krusch, M
    Kaiser, S
    Jobst, K
    Smirnow, I
    Wagner, A
    Steinle, A
    Salih, HR
    [J]. CANCER RESEARCH, 2005, 65 (14) : 6321 - 6329
  • [2] Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D
    Bacon, L
    Eagle, RA
    Meyer, M
    Easom, N
    Young, NT
    Trowsdale, J
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 173 (02) : 1078 - 1084
  • [3] MIC and other NKG2D ligands: from none to too many
    Bahram, S
    Inoko, H
    Shiina, T
    Radosavljevic, M
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2005, 17 (05) : 505 - 509
  • [4] BAHRAM S, 1994, P NATL ACAD SCI USA, V96, P6879
  • [5] Chk1 and Chk2 kinases in checkpoint control and cancer
    Bartek, J
    Lukas, J
    [J]. CANCER CELL, 2003, 3 (05) : 421 - 429
  • [6] Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
    Bauer, Stefan
    Groh, Veronika
    Wu, Jun
    Steinle, Alexander
    Phillips, Joseph H.
    Lanier, Lewis L.
    Spies, Thomas
    [J]. JOURNAL OF IMMUNOLOGY, 2018, 200 (07) : 2231 - 2233
  • [7] BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia
    Boissel, Nicolas
    Rea, Delphine
    Tieng, Vannary
    Dulphy, Nicolas
    Brun, Manuel
    Cayuela, Jean-Michel
    Rousselot, Philippe
    Tamouza, Ryad
    Le Bouteiller, Philippe
    Mahon, Francois-Xavier
    Steinle, Alexander
    Charron, Dominique
    Dombret, Herve
    Toubert, Antoine
    [J]. JOURNAL OF IMMUNOLOGY, 2006, 176 (08) : 5108 - 5116
  • [8] HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
    Braud, VM
    Allan, DSJ
    O'Callaghan, CA
    Söderström, K
    D'Andrea, A
    Ogg, GS
    Lazetic, S
    Young, NT
    Bell, JI
    Phillips, JH
    Lanier, LL
    McMichael, AJ
    [J]. NATURE, 1998, 391 (6669) : 795 - 799
  • [9] How NKG2D ligands trigger autoimmunity?
    Caillat-Zucman, Sophie
    [J]. HUMAN IMMUNOLOGY, 2006, 67 (03) : 204 - 207
  • [10] Carayannopoulos LN, 2002, EUR J IMMUNOL, V32, P597, DOI 10.1002/1521-4141(200203)32:3<597::AID-IMMU597>3.3.CO